Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 9:44 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1561–1584 of 13,609 matching trials from the live ClinicalTrials.gov search.
Not listed Not applicable Interventional

Dapsone Prurigo Study

NCT01870050
Conditions
Lichen Simples Chronicus and Prurigo
Interventions
Dapsone gel - verum
Drug
Lead sponsor
Cook County Health
Government
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Completed No phase listed Observational Results available

Ultrasound Elastography of Breast Lesions

NCT00716482
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
SuperSonic Imagine
Industry
Eligibility
21 Years and older · Female only
Enrollment
1,681 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • New Haven, Connecticut + 3 more
Conditions
Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Metastatic Melanoma
Interventions
Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Therapeutic Tumor Infiltrating Lymphocytes
Biological · Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Breast Neoplasms, Breast Diseases
Interventions
Anastrozole, Palbociclib, Trastuzumab, Pertuzumab
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
New York, New York
Conditions
Melanoma (Skin)
Interventions
recombinant interferon alfa, lymphangiography, Observation
Biological · Procedure · Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 70 Years
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
4
States / cities
Birmingham, Alabama • Louisville, Kentucky • New Brunswick, New Jersey + 1 more
Conditions
Generalized Pustular Psoriasis
Interventions
Spesolimab
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
12 Years to 75 Years
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Auburn Hills, Michigan • New York, New York
Conditions
Breast Cancer
Interventions
cyclophosphamide, doxorubicin hydrochloride, paclitaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
2,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
18
States / cities
Scottsdale, Arizona • Peoria, Illinois • Urbana, Illinois + 15 more
Conditions
Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
pegylated liposomal doxorubicin hydrochloride, docetaxel, trastuzumab, laboratory biomarker analysis
Drug · Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Breast Cancer
Interventions
chemotherapy, endocrine therapy, DNA methylation analysis, protein analysis, laboratory biomarker analysis, questionnaire administration, adjuvant therapy, conventional surgery, radiation therapy
Drug · Genetic · Other + 2 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Acne Vulgaris
Interventions
Skinpen Prescision System
Device
Lead sponsor
Crown Laboratories, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Renal Cancer, Melanoma
Interventions
Aldesleukin, Sorafenib
Drug
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Psoriatic Arthritis
Interventions
Secukinumab, Adalimumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
853 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
19
States / cities
Fountain Valley, California • Fullerton, California • La Mesa, California + 16 more
Completed Phase 1Phase 2 Interventional Results available

Gentamicin for RDEB

NCT03012191
Conditions
Recessive Dystrophic Epidermolysis Bullosa
Interventions
Gentamicin Sulfate
Drug
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic or Unresectable Melanoma, Non-small Cell Lung Cancer (NSCLC), Metastatic Castration-resistant Prostate Cancer (mCRPC), Malignant Pleural Mesothelioma (MPM), Triple Negative Breast Cancer (TNBC), Metastatic Urothelial Carcinoma, Cervical Cancer, Diffuse Large B Cell Lymphoma (DLBCL), Richter Transformation, Microsatellite Stable Colorectal Carcinoma
Interventions
NX-1607, Paclitaxel
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
10
States / cities
Duarte, California • Los Angeles, California • San Francisco, California + 7 more
Conditions
Breast Cancer
Interventions
Acupuncture, Sham Acupuncture
Procedure
Lead sponsor
Columbia University
Other
Eligibility
45 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Conditions
Hereditary Angioedema, HAE, Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2
Interventions
ADX-324, Placebo
Drug
Lead sponsor
ADARx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Litchfield Park, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 16 more
Conditions
Chemotherapy Adjuvant, Breast Cancer
Interventions
Dignicap System
Device
Lead sponsor
Target Health Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
4
States / cities
San Francisco, California • New York, New York • Winston-Salem, North Carolina
Conditions
Breast Cancer
Interventions
Cisplatin, carboplatin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
10
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 5 more
Conditions
Solid Tumors
Interventions
Navlimetostat, Daraxonrasib, Temozolomide, Pumitamig, Pemetrexed, Carboplatin, Nab-paclitaxel, Gemcitabine, Paclitaxel, Cisplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
254 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
16
States / cities
San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 10 more
Conditions
Actinic Keratosis
Interventions
Aldara (imiquimod 5% cream), Vehicle cream
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Loma Linda, California
Conditions
Melanoma, Neoplasm Metastasis
Interventions
CC 5013
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
25
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 18 more
Conditions
Breast Cancer, Colorectal Cancer, Lung Cancer, Malignant Mesothelioma, Prostate Cancer, Psychosocial Effects of Cancer and Its Treatment, Thymoma and Thymic Carcinoma
Interventions
educational intervention, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Breast Cancer
Interventions
Onartuzumab, Bevacizumab, Paclitaxel, Bevacizumab Placebo, Onartuzumab Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
23
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more
Conditions
Metastatic Breast Cancer, Solid Tumors
Interventions
Alisertib, MLN0128
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 101 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Aurora, Colorado